A Study to Identify the Risk Factors and their Relationship with Mucormycosis Severity in COVID Pneumonia



Abstract Views
355

Downloads
224

Citations

Share

##plugins.themes.bootstrap3.article.sidebar##

Submitted Oct 23, 2021
Published Feb 1, 2022
10.24018/clinicmed.2022.3.1.138

Abstract viewed = 355 times

Table of Contents

##plugins.themes.bootstrap3.article.main##

Background: Mucormycosis is an infection caused by a fungus that is present naturally in the environment. There has been an increased number of mucormycosis infections reported during COVID-19 and post COVID period. Dysregulated immune system due to COVID-19 and steroid use in the treatment which suppresses the immune system predisposes to this fungal infection. Patients with Diabetes Mellitus & those who receive humidified oxygen during COVID-19 are found to be at higher risk of developing mucormycosis.

Methodology: 60 patients with mucormycosis admitted in the mucormycosis ward of SVRRGGH, Tirupathi, Andhra Pradesh, India in June 2021 are enrolled and retrospectively studied. Data were collected according to prestructured proforma about risk factors which include the previous history of Diabetes, CT severity score during COVID-19, and use of steroids and oxygen during the period of COVID-19.

Results:  A total of 60 patients with mucormycosis were included in the study with a mean age of 49.25+/-10.29. 80% of the patients were males & 20% were females. 38.33% had mild COVID-19 (CTSS 0-7), 45% had moderate disease (CTSS 8-17) and 16.66% had severe disease (CTSS 18-25). 70% had stage 2, 18.33% had stage 3 and 10% had stage 4 mucormycosis. Out of total patients, 78.33% were found to have a previous history of diabetes or newly detected diabetes. 60% of the patients had a history of humidified oxygen inhalation & 58.33% of the patients had received steroids during COVID-19.

Conclusion: Male preponderance was observed in the study. Diabetes Mellitus, steroid use, humidified oxygen usage are the identifiable risk factors in mucormycosis associated with COVID-19. CT severity score is directly proportional to mucormycosis severity in the present study.

Keywords: COVID-19, CT severity score, diabetes mellitus, mucormycosis, steroid, oxygen

References

  1. Sarkar S, Gokhale T, Choudhury SS, Deb AK. COVID-19 and orbital mucormycosis. Indian J Ophthalmol. 2021; 69: 1002-4.
     Google Scholar
  2. Alekesyev K, Didenko L, Chaudhry B. Rhinocerebral mucormycosis and COVID-19 pneumonia. J Med Cases. 2021; 12(3): 85–89.
     Google Scholar
  3. Singh AK, Singh R, Joshi SR, Misra A. Mucormycosis in COVID-19: A systematic review of cases reported worldwide and in India. Diabetes Metab Syndr. 2021; 15(4): 102146.
     Google Scholar
  4. Lackner N, Posch W, Lass-Flörl C. Microbiological and Molecular Diagnosis of Mucormycosis: From Old to New. Microorganisms. 2021; 9(7): 1518.
     Google Scholar
  5. Patel A, Kaur H, Xess I. A multicentre observational study on the epidemiology, risk factors, management, and outcomes of mucormycosis in India. Clin Microbiol Infect. 2020; 26(7): 944.e9-944.e15.
     Google Scholar
  6. Sugar AM. Mucormycosis. Clin Infect Dis. 1992; 14: S126e9.
     Google Scholar
  7. Honavar SG. Code Mucor: Guidelines for the Diagnosis, Staging, and Management of Rhino-Orbito-Cerebral Mucormycosis in the Setting of COVID-19. Indian J Ophthalmol. 2021; 69(6): 1361-1365.
     Google Scholar
  8. Sen M, Honavar SG, Bansal R, Sengupta S, Rao R, Kim U, et al. Epidemiology, clinical profile, management, and outcome of COVID-19-associated rhino-orbital-cerebral mucormycosis in 2826 patients in India - Collaborative OPAI-IJO Study on Mucormycosis in COVID-19 (COSMIC), Report 1. Indian J Ophthalmol. 2021; 69(7): 1670-1692.
     Google Scholar
  9. Prakash H, Chakrabarti A. Epidemiology of Mucormycosis in India. Microorganisms. 2021; 9(3): 523.
     Google Scholar
  10. Saeed GA, Gaba W, Shah A, Al Helali AA, Raidullah E, Al Ali AB, et al. Correlation between Chest CT Severity Scores and the Clinical Parameters of Adult Patients with COVID-19 Pneumonia. Radiol Res Pract. 2021; 2021: 6697677.
     Google Scholar
  11. Chander J, Kaur M, Singla N, Punia RPS, Singhal SK, Attri AK, et al. Mucormycosis: battle with the deadly enemy over a five-year period in India. J Fungi 2018; 4: 46.
     Google Scholar
  12. Ramaswami A, Sahu AK, Kumar A, Suresh S, Nair A, Gupta D, et al. COVID-19-associated mucormycosis presenting to the Emergency Department—an observational study of 70 patients, QJM: An International Journal of Medicine. 2021.
     Google Scholar
  13. Singh Y, Ganesh V, Kumar S, Patel N, Aggarwala R, Soni KD, et al. (July 03, 2021) Coronavirus Disease-Associated Mucormycosis from a Tertiary Care Hospital in India: A Case Series. Cureus. 13(7): e16152.
     Google Scholar
  14. Sharma, S., Grover, M., Bhargava, S., Samdani, S., & Kataria, T. Post coronavirus disease mucormycosis: A deadly addition to the pandemic spectrum. The Journal of Laryngology & Otology. 2021; 135(5): 442-447.
     Google Scholar
  15. Kumar M, Sarma DK, Shubham S, Kumawat M, Verma V, Singh B, et al. Mucormycosis in COVID-19 pandemic: Risk factors and linkages. Curr Res Microb Sci. 2021; 2: 100057.
     Google Scholar
  16. Staats CC, Kmetzsch L, Schrank A, Vainstein MH. Fungal zinc metabolism and its connections to virulence. Front Cell Infect Microbiol. 2013; 3: 65.
     Google Scholar
  17. Leonardelli F, Macedo D, Dudiuk C, Theill L, Cabeza MS, Gamarra S, et al. In Vitro Activity of Combinations of Zinc Chelators with Amphotericin B and Posaconazole against Six Mucorales Species. Antimicrob Agents Chemother. 2019; 63(5): e00266-19.
     Google Scholar